B

Surgical Dogma, Reality, and Aspirations After Neoadjuvant Therapy for NSCLC

By Brendon Stiles 4 Videos
102 views
April 29, 2024
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

35:40
Balazs Halmos

Year in Review: Lung Cancer

17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
27:04
Fengting Yan

Cancer Screening Molecular Tools

25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
14:49
Vivek Subbiah

Year in Review: Precision Medicine

17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
30:27
Insights from 2023 ESMO Annual Meeting

Perioperative Immunotherapy Strategies in Resectable NSCLC After ESM…

Feat. G. Mountzios
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West
20:52
Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle
16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC